CA2915386A1 - Cb1 receptor antigen-binding proteins and uses thereof - Google Patents

Cb1 receptor antigen-binding proteins and uses thereof Download PDF

Info

Publication number
CA2915386A1
CA2915386A1 CA2915386A CA2915386A CA2915386A1 CA 2915386 A1 CA2915386 A1 CA 2915386A1 CA 2915386 A CA2915386 A CA 2915386A CA 2915386 A CA2915386 A CA 2915386A CA 2915386 A1 CA2915386 A1 CA 2915386A1
Authority
CA
Canada
Prior art keywords
antigen
binding protein
seq
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2915386A
Other languages
English (en)
French (fr)
Inventor
Peter Coward
Steven A. Moore, Jr.
Shi-Yuan Meng
Mei-Mei Tsai
Chadwick Terence King
Aaron Avraham NAZARIAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2915386A1 publication Critical patent/CA2915386A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2915386A 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof Pending CA2915386A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361839458P 2013-06-26 2013-06-26
US61/839,458 2013-06-26
PCT/US2014/044164 WO2014210205A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
CA2915386A1 true CA2915386A1 (en) 2014-12-31

Family

ID=51177217

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2915386A Pending CA2915386A1 (en) 2013-06-26 2014-06-25 Cb1 receptor antigen-binding proteins and uses thereof

Country Status (6)

Country Link
US (1) US10227406B2 (enExample)
EP (1) EP3013860B1 (enExample)
JP (6) JP6562912B2 (enExample)
AU (1) AU2014302410B2 (enExample)
CA (1) CA2915386A1 (enExample)
WO (1) WO2014210205A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727018C1 (ru) * 2015-09-30 2020-07-17 Берд Рок Байо, Инк. Антитела, способные связываться с человеческим каннабиноидным рецептором 1 (cb1)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6598844B2 (ja) 2014-03-27 2019-10-30 バード・ロック・バイオ・インコーポレイテッド ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
JP2020537506A (ja) 2017-10-04 2020-12-24 アムジエン・インコーポレーテツド トランスサイレチン免疫グロブリン融合物
CN112218684A (zh) 2018-04-30 2021-01-12 武田药品工业株式会社 大麻素受体1型(cb1)结合蛋白及其用途
JP7430624B2 (ja) 2020-11-27 2024-02-13 株式会社ブリヂストン タイヤ組立体
KR102707476B1 (ko) 2021-01-28 2024-09-20 주식회사 파미노젠 피라졸-카르복스아미드 유도체 화합물 및 이의 용도
JPWO2023234406A1 (enExample) 2022-06-03 2023-12-07
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023232A2 (en) * 2003-09-04 2005-03-17 Affibody Ab Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders.
US7655685B2 (en) 2007-11-02 2010-02-02 Jenrin Discovery, Inc. Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
EP2382204B1 (en) * 2008-12-23 2018-07-11 Merck Sharp & Dohme Corp. Pyrimidine derivatives as gpcr modulators for use in the treatment of obesity and diabetes
US20130059890A1 (en) 2009-12-18 2013-03-07 Sydney West Area Health Service Antiviral agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2727018C1 (ru) * 2015-09-30 2020-07-17 Берд Рок Байо, Инк. Антитела, способные связываться с человеческим каннабиноидным рецептором 1 (cb1)
US11421026B2 (en) 2015-09-30 2022-08-23 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor

Also Published As

Publication number Publication date
HK1224311A1 (en) 2017-08-18
AU2014302410B2 (en) 2019-06-13
US10227406B2 (en) 2019-03-12
JP2022037087A (ja) 2022-03-08
JP2020196763A (ja) 2020-12-10
JP2016523910A (ja) 2016-08-12
JP7018104B2 (ja) 2022-02-09
EP3013860A1 (en) 2016-05-04
JP2023171760A (ja) 2023-12-05
JP2018201516A (ja) 2018-12-27
JP6562912B2 (ja) 2019-08-21
AU2014302410A1 (en) 2015-12-24
EP3013860B1 (en) 2018-12-12
WO2014210205A1 (en) 2014-12-31
JP2025163008A (ja) 2025-10-28
US20160145333A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
US20240327526A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
US10227406B2 (en) Cannabinoid receptor-1 (CB1) monoclonal antibodies
US9493554B2 (en) Methods of treating retinal disorders with anti-apelin antibodies
KR102866306B1 (ko) 신경 성장 인자에 대한 단일 클론 항체, 및 이의 코딩 유전자 및 용도
JP2024001292A (ja) 多特異性Ｗｎｔ代替分子及びその使用
HK1224311B (en) Cb1 receptor antigen-binding proteins and uses thereof
JP2024533616A (ja) 新規のＷｎｔアゴニスト抗体およびその治療的使用
EA044828B1 (ru) Моноклональное антитело против фактора роста нервов, кодирующий его ген и его применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190325

EEER Examination request

Effective date: 20190325

EEER Examination request

Effective date: 20190325

EEER Examination request

Effective date: 20190325

EEER Examination request

Effective date: 20190325

EEER Examination request

Effective date: 20190325

EEER Examination request

Effective date: 20190325